• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Hercules Capital Reports Second Quarter 2021 Financial Results

    7/29/21 4:10:00 PM ET
    $ZETA
    $IPSC
    $HCXY
    $XMTR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ZETA alert in real time by email

    Record Year-to-Date Total Debt and Equity Commitments of $971.7 Million

    Record Year-to-Date Total Fundings of $634.0 Million

    Surpassed $12.0 Billion in Cumulative Total Debt Commitments since Inception

    Q2 2021 Net Asset Value per Share Increased 3.1% to $11.71 from Q1 2021

    Record Undistributed Earnings Spillover of $160.2 Million, or $1.38(1) per Ending Shares Outstanding

    Q2 2021 Financial Achievements and Highlights

    • Net Investment Income "NII" of $37.0 million, or $0.32 per share, an increase of 3.6% year-over-year
    • Total Investment Income of $69.6 million, an increase of 2.3% year-over-year
    • Total gross new debt and equity commitments of $440.8 million
      • Net Hercules' debt and equity commitments of $399.7 million(2)
    • Total gross fundings of $278.7 million
      • Net Hercules' fundings of $246.9 million(2)
    • Unscheduled early principal repayments or "early loan repayments" of $167.9 million
    • $610.0 million of available liquidity, subject to existing terms and covenants
    • 11.8% Return on Average Equity "ROAE" (NII/Average Equity)
    • 5.9% Return on Average Assets "ROAA" (NII/Average Assets)
    • GAAP leverage of 87.7% and regulatory leverage of 83.8%(3)
    • Net Asset Value "NAV" increased to $11.71 from $11.36, an increase of 3.1% from Q1 2021
    • 12.7% GAAP Effective Yield and 11.5% Core Yield(4), a non-GAAP measure

    Year-to-date ending June 30, 2021 Financial Highlights

    • NII of $71.5 million, or $0.62 per share
      • Total investment income of $138.3 million
    • Record new equity and debt commitments of $971.7 million, an increase of 85.8% year-over-year
      • Record total fundings of $634.0 million, an increase of 73.3% year-over-year
    • Net debt investment portfolio growth of $139.3 million
    • Unscheduled early loan repayments of $359.4 million

    Footnotes:

    1. $1.40 per Weighted Average Shares Outstanding
    2. Net Hercules' commitments and fundings are net of what was assigned to the private funds during the quarter
    3. Regulatory leverage represents debt-to-equity ratio, excluding the Company's Small Business Administration "SBA" debentures
    4. Core Yield excludes early loan repayments and one-time fees, and includes income and fees from expired commitments

     

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the second quarter ended June 30, 2021.

    "During Q2 2021, Hercules generated 100% coverage of our base dividend distribution with NII, delivered solid NAV accretion and maintained our strong liquidity position to fund our disciplined and controlled growth strategy," stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. "As a result, the Company was able to offset elevated repayment activities, deliver net debt portfolio growth of nearly $57 million and achieve the highest internal credit rating in our history. This strong operating performance extended the momentum from Q1, which led to record levels of new debt and equity commitments and total fundings of nearly $972 million and $634 million, respectively, for the first half of 2021."

    Bluestein added, "With the public and private equity markets performing exceptionally well, our technology and life sciences portfolio companies are benefitting from multiple ways to raise new capital or achieve liquidity events. Our equity and warrant portfolio has continued to march in parallel with the public markets, with 26 of our portfolio companies announcing or completing exit events year-to-date, of which 10 have completed initial public offerings. This has generated record undistributed earnings spillover of over $160 million, giving us additional flexibility to continue to invest in our team and platform for the long term while also delivering strong shareholder returns."

    Q2 2021 Review and Operating Results

    Debt Investment Portfolio

    Hercules delivered new debt and equity commitments totaling $440.8 million and fundings totaling $278.7 million.

    During the second quarter, Hercules realized early loan repayments of $167.9 million, which along with normal scheduled amortization of $19.6 million, resulted in total debt repayments of $187.5 million.

    The new debt investment origination and funding activities lead to a net debt investment portfolio increase of $56.8 million during the second quarter, on a cost basis.

    The Company's total investment portfolio, (at cost and fair value) by category, quarter-over-quarter is highlighted below:

    Total Investment Portfolio: Q2 2021 to Q1 2021

    Equity & Other
    (in millions) Debt Investments Warrants Total Portfolio
    Balances at Cost at 3/31/21

    $

    2,182.0

     

    $

    196.5

     

    $

    25.3

     

    $

    2,403.8

     

    New fundings(a)

     

    268.1

     

     

    10.1

     

     

    0.9

     

     

    279.1

     

    Fundings assigned to External Funds

     

    (30.3

    )

     

    (1.3

    )

     

    (0.1

    )

     

    (31.7

    )

    Principal payments received on investments

     

    (19.6

    )

     

    —

     

     

    —

     

     

    (19.6

    )

    Early payoffs

     

    (167.9

    )

     

    —

     

     

    —

     

     

    (167.9

    )

    Net changes attributed to conversions, liquidations, and fees

     

    6.5

     

     

    (70.2

    )

     

    (1.0

    )

     

    (64.7

    )

    Net activity during Q2 2021

     

    56.8

     

     

    (61.4

    )

     

    (0.2

    )

     

    (4.8

    )

    Balances at Cost at 6/30/21

    $

    2,238.8

     

    $

    135.1

     

    $

    25.1

     

    $

    2,399.0

     

     
     
    Balances at Value at 3/31/21

    $

    2,185.1

     

    $

    237.3

     

    $

    42.0

     

    $

    2,464.4

     

    Net activity during Q2 2021

     

    56.8

     

     

    (61.4

    )

     

    (0.2

    )

     

    (4.8

    )

    Net change in unrealized appreciation (depreciation)

     

    1.5

     

     

    55.1

     

     

    4.9

     

     

    61.5

     

    Total net activity during Q2 2021

     

    58.3

     

     

    (6.3

    )

     

    4.7

     

     

    56.7

     

    Balances at Value at 6/30/21

    $

    2,243.4

     

    $

    231.0

     

    $

    46.7

     

    $

    2,521.1

     

     
    (a) New fundings amount includes $3.0 million associated with revolver loans during Q2 2021.

    Debt Investment Portfolio Balances by Quarter

    (in millions) Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020
     
    Ending Balance at Cost

    $2,238.8

    $2,182.0

    $2,099.5

    $2,283.7

    $2,278.9

     
    Weighted Average Balance

    $2,192.0

    $2,119.0

    $2,246.0

    $2,217.0

    $2,248.0

     

    Debt Investment Portfolio Composition by Quarter

    (% of debt investment portfolio) Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020
     
    First Lien Senior Secured

    82.1%

    82.7%

    84.2%

    85.5%

    83.5%

     
    Floating Rate w/Floors

    96.8%

    96.8%

    96.9%

    97.9%

    97.9%

     

    Effective Portfolio Yield and Core Portfolio Yield ("Core Yield")

    The effective yield on Hercules' debt investment portfolio was 12.7% during Q2 2021, as compared to 13.2% for Q1 2021. The Company realized $167.9 million of early loan repayments in Q2 2021 compared to $191.5 million in Q1 2021, or a decrease of 12.3%. Effective yields generally include the effects of fees and income accelerations attributed to early loan repayments, and other one-time events. Effective yields are materially impacted by the elevated or reduced levels of early loan repayments and derived by dividing total investment income by the weighted average earning investment portfolio assets outstanding during the quarter, which excludes non-interest earning assets such as warrants and equity investments.

    Core yield, a non-GAAP measure, was 11.5% during Q2 2021, within the Company's expected range of 11.0% to 12.0%, and decreased slightly compared to 11.6% in Q1 2021. Hercules defines core yield as yields that generally exclude any benefit from income related to early repayments attributed to the acceleration of unamortized income and prepayment fees and includes income from expired commitments.

    Income Statement

    Total investment income increased to $69.6 million for Q2 2021, compared to $68.0 million in Q2 2020. The increase is primarily attributable to an increase in total fee income between periods.

    Non-interest and fee expenses were $17.1 million in Q2 2021 versus $15.6 million for Q2 2020. The increase was due to higher employee compensation and stock-based compensation expenses.

    Interest expense and fees were $16.7 million in Q2 2021, compared to $16.7 million in Q2 2020.

    The Company had a weighted average cost of borrowings comprised of interest and fees, of 5.4% in Q2 2021, as compared to 5.0% for Q2 2020. The increase is primarily due to the acceleration of fee recognition for the partial paydown of the SBA debentures and securitizations, due to the reinvestment period ending.

    NII – Net Investment Income

    NII for Q2 2021 was $37.0 million, or $0.32 per share, based on 114.7 million basic weighted average shares outstanding, compared to $35.7 million, or $0.32 per share, based on 111.6 million basic weighted average shares outstanding in Q2 2020. The increase is primarily attributable to an increase in the total fee income between periods.

    Continued Credit Discipline and Strong Credit Performance

    Hercules' net cumulative realized gain/(loss) position, since its first origination activities in October 2004 through June 30, 2021, (including net loan, warrant and equity activity) on investments, totaled ($86.2) million, on a GAAP basis, spanning over 16 years of investment activities.

    When compared to total new debt investment commitments during the same period of over $12.0 billion, the total realized gain/(loss) since inception of ($86.2) million represents approximately 72 basis points "bps," or 0.72%, of cumulative debt commitments, or an effective annualized loss rate of 4.0 bps, or 0.04%.

    Realized Gains/(Losses)

    During Q2 2021, Hercules had net realized losses of ($14.3) million comprised of gross realized gains of $47.8 million due to the sale of equity and warrant investments, offset by ($62.1) million of gross realized losses primarily due to the write-off of one legacy equity investment that had a fair value of $0.

    Unrealized Appreciation/(Depreciation)

    During Q2 2021, Hercules recorded $60.0 million of net unrealized appreciation, primarily from net unrealized appreciation from our debt, equity and warrant investments.

    Portfolio Asset Quality

    As of June 30, 2021, the weighted average grade of the debt investment portfolio, at fair value, improved to 1.93, compared to 2.01 as of March 31, 2021, based on a scale of 1 to 5, with 1 being the highest quality. Hercules' policy is to generally adjust the credit grading down on its portfolio companies as they approach their expected need for additional growth equity capital to fund their respective operations for the next 9-14 months. Various companies in the Company's portfolio will require additional rounds of funding from time to time to maintain their operations.

    Additionally, Hercules may selectively downgrade portfolio companies, from time to time, if they are not meeting the Company's financing criteria, or underperforming relative to their respective business plans.

    As of June 30, 2021, grading of the debt investment portfolio at fair value, excluding warrants and equity investments, was as follows:

    Credit Grading at Fair Value, Q2 2021 - Q2 2020 ($ in millions)

    Q2

    2021

     

     

    Q1

    2021

     

     

    Q4

    2020

     

     

    Q3

    2020

     

     

    Q2

    2020

     

    Grade 1 - High

    $

    637.2

    28.4

    %

    $

    497.5

    22.8

    %

    $

    411.0

    19.6

    %

    $

    406.5

    17.9

    %

    $

    443.6

    20.1

    %

    Grade 2

    $

    1,192.7

    53.1

    %

    $

    1,240.7

    56.8

    %

    $

    1,027.9

    49.1

    %

    $

    1,053.1

    46.5

    %

    $

    877.9

    39.6

    %

    Grade 3

    $

    403.8

    18.0

    %

    $

    426.2

    19.5

    %

    $

    621.3

    29.7

    %

    $

    772.3

    34.1

    %

    $

    849.7

    38.3

    %

    Grade 4

    $

    8.4

    0.4

    %

    $

    20.4

    0.9

    %

    $

    25.3

    1.2

    %

    $

    26.7

    1.2

    %

    $

    25.0

    1.1

    %

    Grade 5 - Low

    $

    1.3

    0.1

    %

    $

    0.2

    0.0

    %

    $

    8.9

    0.4

    %

    $

    5.9

    0.3

    %

    $

    20.1

    0.9

    %

     
    Weighted Avg.

     

    1.93

     

    2.01

     

    2.16

     

    2.22

     

    2.30

    Non-Accruals

    Non-accruals decreased slightly as a percentage of the overall investment portfolio in the second quarter of 2021. As of June 30, 2021, the Company had three (3) debt investments on non-accrual with an investment cost and fair value of approximately $23.0 million and $7.7 million, respectively, or 1.0% and 0.3% as a percentage of the Company's total investment portfolio at cost and value, respectively.

    Compared to March 31, 2021, the Company had four (4) debt investments on non-accrual with an investment cost and fair value of approximately $24.1 million and $8.0 million, respectively, or 1.0% and 0.3% as a percentage of the total investment portfolio at cost and value, respectively.

    Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020
     
    Total Investments at Cost

    $2,399.0

    $2,403.8

    $2,315.4

    $2,505.8

    $2,501.4

     
    Loans on non-accrual as a % of Total
    Investments at Value

    0.3%

    0.3%

    0.5%

    0.3%

    0.5%

     
    Loans on non-accrual as a % of Total

    1.0%

    1.0%

    1.3%

    0.9%

    2.4%

    Investments at Cost

    Liquidity and Capital Resources

    The Company ended Q2 2021 with $610.0 million in available liquidity, including $18.4 million in unrestricted cash and cash equivalents, and $591.6 million in available credit facilities and SBA Debentures, subject to existing terms and advance rates and regulatory and covenant requirements.

    Bank Facilities

    As of June 30, 2021, there were $1.7 million outstanding borrowings under the Hercules' $400.0 million committed credit facility with Union Bank as Agent and no outstanding borrowings under the Hercules' $75.0 million committed credit facility with Wells Fargo Capital Finance.

    Leverage

    As of June 30, 2021, Hercules' GAAP leverage ratio, including its Small Business Administration "SBA" debentures, was 87.7%. Hercules' regulatory leverage, or debt-to-equity ratio, excluding its SBA debentures, was 83.8% and net regulatory leverage, a non-GAAP measure (excluding cash of approximately $18.5 million), was 82.4%. Hercules' net leverage ratio, including its SBA debentures, was 86.4%.

    Available Unfunded Commitments – Representing 12.7% of Total Assets

    The Company's unfunded commitments and contingencies consist primarily of unused commitments to extend credit in the form of loans to select portfolio companies. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones in order to gain access to additional funding. Furthermore, the Company's credit agreements contain customary lending provisions that allow us relief from funding obligations for previously made commitments. In addition, since a portion of these commitments may also expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements.

    As of June 30, 2021, the Company had $327.3 million of available unfunded commitments at the request of the portfolio company and unencumbered by any milestones, including undrawn revolving facilities, representing 12.7% of Hercules' total assets. This increased from the previous quarter of $257.9 million of available unfunded commitments or 10.0% of Hercules' total assets.

    Existing Pipeline and Signed Term Sheets

    After closing $440.8 million in new debt and equity commitments in Q2 2021, Hercules has pending commitments of $402.5 million in signed non-binding term sheets outstanding as of July 26, 2021. Since the close of Q2 2021 and as of July 26, 2021, Hercules has closed new debt and equity commitments of $27.0 million and funded $23.4 million.

    Signed non-binding term sheets are subject to satisfactory completion of Hercules' due diligence and final investment committee approval process as well as negotiations of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing and some portion may be assigned or allocated to private funds managed by Hercules Adviser prior to or after closing. It is important to note that not all signed non-binding term sheets are expected to close and do not necessarily represent future cash requirements or investments.

    Net Asset Value

    As of June 30, 2021, the Company's net assets were $1.36 billion, compared to $1.32 billion at the end of Q1 2021. NAV per share increased 3.1% to $11.71 on 115.9 million outstanding shares of common stock as of June 30, 2021, compared to $11.36 on 115.8 million outstanding shares of common stock as of March 31, 2021. The increase in NAV per share was primarily attributed to the net change in unrealized appreciation and a decrease in liabilities between periods.

    Interest Rate Sensitivity

    Hercules has an asset sensitive debt investment portfolio with 96.8% of its debt investment portfolio being priced at floating interest rates as of June 30, 2021, with a Prime or LIBOR-based interest rate floor, combined with 99.9% of its outstanding debt borrowings bearing fixed interest rates, leading to higher net investment income sensitivity.

    Based on Hercules' Consolidated Statement of Assets and Liabilities as of June 30, 2021, the following table shows the approximate annualized increase/(decrease) in components of net income resulting from operations of hypothetical base rate changes in interest rates, such as Prime Rate, assuming no changes in Hercules' debt investments and borrowings. These estimates are subject to change due to the impact from active participation in the Company's equity ATM program and any future equity offerings.

    (in thousands) Interest Interest Net EPS(2)
    Basis Point Change Income(1) Expense Income

    (75)

    $

    (3)

    $

    (21)

    $

    18

    $

    -

    (50)

    $

    (3)

    $

    (14)

    $

    11

    $

    -

    (25)

    $

    (3)

    $

    (7)

    $

    4

    $

    -

    25

    $

    3,425

    $

    7

    $

    3,418

    $

    0.03

    50

    $

    6,893

    $

    14

    $

    6,879

    $

    0.06

    75

    $

    10,339

    $

    21

    $

    10,318

    $

    0.09

    100

    $

    13,862

    $

    28

    $

    13,834

    $

    0.12

    200

    $

    29,236

    $

    56

    $

    29,180

    $

    0.25

     
    (1) Source: Hercules Capital Form 10-Q for Q2 2021
    (2) EPS calculated on basic weighted shares outstanding of 114,654. Estimates are subject to change due to impact from active
    participation in the Company's equity ATM program and any future equity offerings.

    Existing Equity and Warrant Portfolio

    Equity Portfolio

    Hercules held equity positions in 67 portfolio companies with a fair value of $229.9 million and a cost basis of $133.8 million as of June 30, 2021. On a fair value basis, 62.6% or $143.9 million is related to existing public equity positions.

    Warrant Portfolio

    Hercules held warrant positions in 93 portfolio companies with a fair value of $46.7 million and a cost basis of $25.1 million as of June 30, 2021. On a fair value basis, 31.4% or $14.7 million is related to existing public warrant positions.

    Portfolio Company IPO and M&A Activity in Q2 2021 and YTD Q3 2021

    IPO Activity

    As of July 26, 2021, Hercules held debt, warrant or equity positions in 10 portfolio companies that have completed their IPOs and eight (8) companies that have registered for their IPOs or have entered into definitive agreements to go public via a merger or special purpose acquisition company "SPAC," including:

    Completed:

    • In July 2021, Hercules' portfolio company Couchbase, Inc. (NASDAQ:BASE), a provider of a leading modern database for enterprise applications, completed its initial public offering of 8.3 million shares of common stock at an initial offering price of $24.00 per share on the Nasdaq Global Select Market. Hercules initially committed $70.0 million in venture debt financing beginning in August 2018 and currently holds warrants for 105,530 shares of common stock as of June 30, 2021.
    • In July 2021, Hercules' portfolio company Wheels Up Partners LLC (NYSE:UP), a provider of subscription club memberships for private-jet flyers, completed its reverse merger initial public offering with Aspirational Consumer Lifestyle Corp. (NYSE:ASPL), a special purpose acquisition company. Hercules initially committed $23.0 million in venture debt financing beginning in December 2017.
    • In July 2021, former Hercules' portfolio company Rapid Micro Biosystems (NASDAQ:RPID), a provider of an automated microbial quality control device and platform, completed its initial public offering of 7.9 million shares of common stock at an initial offering price of $20.00 per share on the Nasdaq Global Select Market. Hercules initially committed $18.0 million in venture debt financing beginning in March 2018.
    • In June 2021, Hercules' portfolio company Century Therapeutics, Inc. (NASDAQ:IPSC), a preclinical biotech developing allogeneic stem cell treatments for multiple cancers, completed its initial public offering of 10.6 million shares of common stock at an initial offering price of $20.00 per share on the Nasdaq Global Select Market. Hercules initially committed $20.0 million in venture debt financing beginning in September 2020 and currently holds warrants for 16,112 shares of common stock as of June 30, 2021.
    • In June 2021, Hercules' portfolio company Sprinklr, Inc. (NYSE:CXM), a developer of a social media management platform designed to provide digital transformation for enterprise businesses, completed its initial public offering of 16.6 million shares of common stock at an initial offering price of $16.00 per share on the New York Stock Exchange. Hercules currently holds 700,000 shares of common stock as of June 30, 2021.
    • In June 2021, Hercules' portfolio company Zeta Global Holdings (NYSE:ZETA), a provider of a SaaS-based customer relationship management (CRM) platform and professional marketing services, completed its initial public offering of 14.8 million shares of common stock at an initial offering price of $10.00 per share on the New York Stock Exchange. Hercules initially committed $15.0 million in venture debt financing beginning in November 2007 and currently holds 295,861 shares of common stock as of June 30, 2021.
    • In June 2021, Hercules' portfolio company Xometry (NASDAQ:XMTR), a leading AI-enabled marketplace for on-demand manufacturing, completed its initial public offering of 6.9 million shares of common stock at an initial offering price of $44.00 per share on the Nasdaq Global Select Market. Hercules initially committed $15.0 million in venture debt financing beginning in May 2018 and currently holds warrants for 87,784 shares of Preferred Series B stock as of June 30, 2021.
    • In June 2021, Hercules' portfolio company Proterra Inc. (NASDAQ:PTRA), a leading commercial electric vehicle technology and manufacturing company, completed its reverse merger initial public offering with ArcLight Clean Transition Corp. (NASDAQ:ACTC), a special purpose acquisition company. Hercules initially committed $30.0 million in venture debt financing beginning in May 2015 and currently holds 455,890 shares of common stock as of June 30, 2021.
    • In June 2021, Hercules' portfolio company 23andMe Inc. (NASDAQ:ME), a provider of consumer DNA-testing products, completed its reverse merger initial public offering with VG Acquisition Corp. (NYSE:VGAC), a special purpose acquisition company. Hercules currently holds 828,360 shares of common stock as of June 30, 2021.
    • In April 2021, Hercules' portfolio company Privia Health Group, Inc. (NASDAQ:PRVA), a technology-driven, national physician enablement company that collaborates with medical groups, health plans and health systems, completed its initial public offering of 19.5 million shares of common stock at an initial offering price of $23.00 per share on the Nasdaq Global Select Market. Hercules initially committed $35.0 million in venture debt financing beginning in August 2016.

    In Registration or SPAC:

    • In July 2021, Hercules' portfolio company Gelesis Inc., a biotherapeutics company advancing superabsorbent hydrogels to treat excess weight and metabolic disorders, announced it has entered into a definitive agreement for a reverse merger initial public offering with Capstar Special Purpose Acquisition Corp. (NYSE:CPSR), a special purpose acquisition company. Upon completion of the merger, the combined company will be listed on the New York Stock Exchange under the ticker symbol "GLS." Hercules initially committed $3.0 million in venture debt financing in August 2008 and currently holds 227,013 shares of common stock, 243,432 shares of Preferred Series A-1 stock and 191,626 shares of Preferred Series A-2 stock as of June 30, 2021.
    • In July 2021, Hercules' portfolio company Nextdoor, a provider of a social network that connects neighbors, announced it has entered into a definitive agreement for a reverse merger initial public offering with Khosla Ventures Acquisition Co. II (NASDAQ:KVSB), a special purpose acquisition company. Upon completion of the merger, the combined company will be listed on the Nasdaq Global Select Market under the ticker symbol "KIND." Hercules currently holds 328,190 shares of common stock as of June 30, 2021.
    • In July 2021, Hercules' portfolio company Planet Labs, an earth data and analytics company, announced it has entered into a definitive agreement for a reverse merger initial public offering with dMY Technology Group IV Inc. (NYSE:DMYQ), a special purpose acquisition company. Upon completion of the merger, the combined company will be listed on the New York Stock Exchange under the ticker symbol "PL." Hercules initially committed $25.0 million in venture debt financing beginning in June 2019 and currently holds warrants for 357,752 shares of common stock as of June 30, 2021.
    • In May 2021, Hercules' portfolio company Valo Health LLC, a technology company using human-centric data and artificial intelligence powered computation to transform the drug discovery and development process, announced it has entered into a definitive agreement for a reverse merger initial public offering with Khosla Ventures Acquisition Co. (NASDAQ:KVAC), a special purpose acquisition company. Upon completion of the merger, the combined company will be listed on the Nasdaq Global Select Market under the ticker symbol "VH." Hercules initially committed $20.0 million in venture debt financing beginning in June 2020 and currently holds 510,308 shares of Preferred Series B stock and warrants for 102,216 shares of common stock as of June 30, 2021.
    • In March 2021, Hercules' portfolio company Rocket Lab, a developer of launch and space systems, announced it has entered into a definitive agreement for a reverse merger initial public offering with Vector Acquisition Corp. (NASDAQ:VACQ), a special purpose acquisition company. Upon completion of the merger, Rocket Lab will be listed on the Nasdaq Global Select Market under the ticker symbol "RKLB." Hercules initially committed $100.0 million in venture debt financing beginning in June 2021.
    • In March 2021, Hercules' portfolio company VELO3D, a developer of metal laser sintering printing machines intended to offer 3D printing, announced it has entered into a definitive agreement for a reverse merger initial public offering with Jaws Spitfire Acquisition Corp. (NYSE:SPFR), a special purpose acquisition company. Upon completion of the merger, VELO3D will be listed on the New York Stock Exchange under the ticker symbol "VLD." Hercules initially committed $12.5 million in venture debt financing beginning in May 2021.
    • In March 2021, Hercules' portfolio company Pineapple Energy, LLC, a U.S. operator and consolidator of residential solar, battery storage and grid services solutions, announced that it entered into a definitive merger agreement with Communications Systems, Inc. (NASDAQ:JCS), and IoT intelligent edge products and services company. Upon closing, CSI will commence doing business as Pineapple Energy, and expects shares of the combined company to continue to trade on the Nasdaq Global Select Market under the new ticker symbol "PEGY." Hercules initially committed $12.3 million in venture debt financing beginning in December 2010 and currently holds 17,647 shares of Class A Units as of June 30, 2021.
    • In February 2021, Nerdy, the parent company of Hercules' portfolio company Varsity Tutors, a technology developer of an online tutoring platform, announced it has entered into a definitive agreement for a reverse merger initial public offering with TPG Pace Tech Opportunities (NYSE:PACE), a special purpose acquisition company. Upon completion of the merger, Nerdy will be listed on the New York Stock Exchange under the ticker symbol "NRDY." Hercules initially committed $50.0 million in venture debt financing beginning in August 2019.

    There can be no assurances that companies that have yet to complete their IPOs will do so.

    M&A Activity

    • In June 2021, Hercules' portfolio company ExtraHop Networks Inc., a cloud-native network detection and response provider, announced that they entered into an agreement to be acquired by private equity firms Bain Capital and Crosspoint Capital for $900.0 million. The acquisition was completed in July. Hercules initially committed $15.0 million in venture debt financing beginning in September 2020 and currently holds warrants for 154,784 shares of common stock as of June 30, 2021.
    • In May 2021, Hercules' portfolio company Greenphire, a leader in global clinical trial financial process automation, announced that they have reached an agreement to be acquired by Thoma Bravo, a leading private equity investment firm focused on the software and technology-enabled services sector. Terms of the acquisition were not disclosed. Hercules initially committed $6.0 million in venture debt (via Ares Capital venture portfolio acquisition) financing beginning in November 2017.
    • In May 2021, Hercules' portfolio company Vela Trading Systems LLC, an independent provider of trading and market access technology for global multi-asset electronic trading, announced that they have merged with Exegy Inc., a provider of low-latency global market data solutions, predictive trading signals and hardware training platforms for the financial services industry. Terms of the acquisition were not disclosed. The merger was backed by Marlin Equity Partners, a global investment firm with over $7.5 billion of capital commitments under management. Hercules initially committed $20.0 million in venture debt financing beginning in June 2017.
    • In April 2021, Hercules' portfolio company Message Systems (a.k.a. SparkPost), a worldwide provider of message management solutions and services for email service providers, social networks and large enterprises, announced that they have reached an agreement to be acquired by MessageBird BV, a provider of cloud-based communications services, for approximately $600.0 million. Hercules initially committed $25.0 million in venture debt financing beginning in January 2015.

    Subsequent Events

    1. As of July 26, 2021, Hercules has:

    1. Funded $23.4 million to new and existing commitments since the close of the second quarter 2021.
    2. Pending commitments (signed non-binding term sheets) of $402.5 million.

    The table below summarizes the Company's year-to-date closed and pending commitments as follows:

    Closed Commitments and Pending Commitments (in millions)

    January 1 – June 30, 2021 Closed Commitments(a)

    $971.7

    Q3 2021 Closed Commitments (as of July 26, 2021)(b)

    $27.0

    Year-to-Date Closed Commitments

    $998.7

    Q3 2021 Pending Commitments (as of July 26, 2021)(b)

    $402.5

    Year-to-Date 2021 Closed and Pending Commitments

    $1,401.2

    Notes:

    1. Closed Commitments may include renewals of existing credit facilities and equity commitments. Not all Closed Commitments result in future cash requirements. Commitments generally fund over the two succeeding quarters from close.
    2. Not all pending commitments (signed non-binding term sheets) are expected to close and do not necessarily represent any future cash requirements.

    2. On July 1, 2021, the Company fully redeemed the aggregate outstanding $75.0 million of principal and $0.6 million of accrued interest pursuant to the redemption terms of the April 2025 Notes Indenture. The Company accelerated $1.5 million of debt issuance costs associated with the extinguishment of the debt.

    Conference Call

    Hercules has scheduled its second quarter 2021 financial results conference call for July 29, 2021 at 2:00 p.m. PT (5:00 p.m. ET). To listen to the call, please dial (877) 304-8957 (or (408) 427-3709 internationally) and reference Conference ID: 1598912 if asked, approximately 10 minutes prior to the start of the call. A taped replay will be made available approximately three hours after the conclusion of the call and will remain available for seven days. To access the replay, please dial (855) 859-2056 or (404) 537-3406 and enter the passcode 1598912.

    About Hercules Capital, Inc.

    Hercules Capital, Inc. (NYSE:HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Since inception (December 2003), Hercules has committed more than $12.0 billion to over 530 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact [email protected], or call 650.289.3060.

    Hercules' common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol "HTGC." In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE:HCXY).

    Category: Earnings

    Forward-Looking Statements

    This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act of 1933, as amended, and Section 21E(b)(2)(B) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 do not apply to forward-looking statements made in periodic reports we file under the Exchange Act.

    The information disclosed in this press release is made as of the date hereof and reflects Hercules' most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Hercules believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Hercules assumes no obligation to update the forward-looking statements for subsequent events.

    HERCULES CAPITAL, INC.
    CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES
    (dollars in thousands, except per share data)
     
    June 30, 2021 December 31, 2020
    Assets
    Investments:
    Non-control/Non-affiliate investments (cost of $2,307,766 and $2,175,651, respectively)

    $ 2,444,849

    $ 2,288,338

    Control investments (cost of $77,901 and $65,257, respectively)

    66,491

    57,400

    Affiliate investments (cost of $13,307 and $74,450, respectively)

    9,750

    8,340

    Total investments in securities, at value (cost of $2,398,974 and $2,315,358, respectively)

    2,521,090

    2,354,078

    Cash and cash equivalents

    18,447

    198,282

    Restricted cash

    5,766

    39,340

    Interest receivable

    19,063

    19,077

    Right of use asset

    8,039

    9,278

    Other assets

    6,167

    3,942

    Total assets

    $ 2,578,572

    $ 2,632,997

     
    Liabilities
    Debt (net of debt issuance costs)(1)

    $ 1,177,515

    $ 1,286,638

    Accounts payable and accrued liabilities

    36,886

    36,343

    Operating lease liability

    7,813

    9,312

    Total liabilities

    $ 1,222,214

    $ 1,332,293

     
    Net assets consist of:
    Common stock, par value

    116

    115

    Capital in excess of par value

    1,163,910

    1,158,198

    Total distributable earnings

    192,332

    133,391

    Total net assets

    $ 1,356,358

    $ 1,291,704

    Total liabilities and net assets

    $ 2,578,572

    $ 2,623,997

     
    Shares of common stock outstanding ($0.001 par value, 200,000,000 authorized)

    115,867

    114,726

    Net asset value per share

    $ 11.71

    $ 11.26

     
    (1) The Company's SBA Debentures, February 2025 Notes, June 2025 Notes, 2033 Notes, April 2025 Notes, 2022 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, 2022 Convertible Notes,
    July 2024 Notes, and March 2026 A and B Notes, as each term is defined herein, are presented net of the associated debt issuance costs for each instrument.
    HERCULES CAPITAL, INC.
    CONSOLIDATED STATEMENTS OF OPERATIONS
    (in thousands, except per share data)
     
    Three Months Ended June 30, Six Months Ended June 30,

    2021

     

    2020

     

    2021

     

    2020

    Investment income:
    Interest and dividend income
    Non-control/Non-affiliate investments

    $ 60,276

    $ 62,667

    $ 123,258

    $ 128,005

    Control investments

    1,029

    731

    1,828

    1,377

    Affiliate investments

    1

    157

    2

    377

    Total interest income

    61,306

    63,555

    125,088

    129,759

    Fee income
    Commitment, facility and loan fee income
    Non-control/Non-affiliate investments

    5,263

    3,511

    8,666

    7,707

    Control investments

    15

    5

    23

    10

    Total commitment, facility and loan fee income

    5,278

    3,516

    8,689

    7,717

    One-time fee income
    Non-control/Non-affiliate investments

    2,975

    897

    4,541

    4,111

    Total one-time fee income

    2,975

    897

    4,541

    4,111

    Total fee income

    8,253

    4,413

    13,230

    11,828

    Total investment income

    69,559

    67,968

    138,318

    141,587

    Operating expenses:
    Interest

    14,490

    15,076

    29,240

    29,608

    Loan fees

    2,220

    1,650

    5,020

    3,444

    General and administrative
    Legal expenses

    526

    991

    954

    1,890

    Tax expenses

    1,746

    899

    3,184

    2,034

    Other expenses

    3,542

    3,973

    6,710

    7,998

    Total general and administrative

    5,814

    5,863

    10,848

    11,922

    Employee compensation
    Compensation and benefits

    8,349

    7,180

    18,153

    15,394

    Stock-based compensation

    2,926

    2,515

    5,670

    4,955

    Total employee compensation

    11,275

    9,695

    23,823

    20,349

    Total gross operating expenses

    33,799

    32,284

    68,931

    65,323

    Expenses allocated to the Adviser Subsidiary

    (1,204)

    —

    (2,137)

    —

    Total net operating expenses

    32,595

    32,284

    66,794

    65,323

    Net investment income

    36,964

    35,684

    71,524

    76,264

    Net realized and change in unrealized appreciation (depreciation) on investments:
    Net realized gain (loss) on investments
    Non-control/Non-affiliate investments

    47,861

    141

    55,631

    7,108

    Affiliate investments

    (62,143)

    —

    (62,143)

    —

    Total net realized gain (loss) on investments

    (14,282)

    141

    (6,512)

    7,108

    Net change in unrealized appreciation (depreciation) on investments
    Non-control/Non-affiliate investments

    3,075

    23,613

    21,097

    (34,816)

    Control investments

    (5,255)

    2,642

    (3,553)

    (5,209)

    Affiliate investments

    62,229

    (315)

    64,338

    (10,305)

    Total net change in unrealized appreciation (depreciation) on investments

    60,049

    25,940

    81,882

    (50,330)

    Total net realized and change in unrealized appreciation (depreciation) on investments:

    45,767

    26,081

    75,370

    (43,222)

    Net increase (decrease) in net assets resulting from operations

    $ 82,731

    $ 61,765

    $ 146,894

    $ 33,042

     
    Net investment income before investment gains and losses per common share:
    Basic

    $ 0.32

    $ 0.32

    $ 0.62

    $ 0.69

    Change in net assets resulting from operations per common share:
    Basic

    $ 0.71

    $ 0.55

    $ 1.27

    $ 0.29

    Diluted

    $ 0.65

    $ 0.55

    $ 1.21

    $ 0.29

    Weighted average shares outstanding:
    Basic

    114,654

    111,558

    114,480

    110,256

    Diluted

    129,572

    111,729

    122,188

    110,504

    Distributions paid per common share:
    Basic

    $ 0.39

    $ 0.32

    $ 0.76

    $ 0.72

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005948/en/

    Get the next $ZETA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZETA
    $IPSC
    $HCXY
    $XMTR

    CompanyDatePrice TargetRatingAnalyst
    Xometry Inc.
    $XMTR
    8/5/2025$41.00Underweight → Neutral
    Cantor Fitzgerald
    Zeta Global Holdings Corp.
    $ZETA
    6/10/2025$20.00Buy
    Needham
    Sprinklr Inc.
    $CXM
    6/3/2025$8.00Neutral
    Cantor Fitzgerald
    Sprinklr Inc.
    $CXM
    2/7/2025Outperform → Mkt Perform
    William Blair
    Privia Health Group Inc.
    $PRVA
    1/10/2025$25.00Buy
    Needham
    Xometry Inc.
    $XMTR
    12/20/2024$48.00Outperform
    Wedbush
    Xometry Inc.
    $XMTR
    12/18/2024$25.00 → $45.00Neutral → Overweight
    Analyst
    Privia Health Group Inc.
    $PRVA
    12/16/2024Outperform
    Macquarie
    More analyst ratings

    $ZETA
    $IPSC
    $HCXY
    $XMTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Follmann Christian sold $7,043 worth of shares (395 units at $17.83) and bought $7,043 worth of shares (395 units at $17.83), increasing direct ownership by 0.22% to 121,212 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    6/5/25 6:38:34 PM ET
    $HTGC
    Investment Managers
    Finance

    Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    5/9/25 4:22:23 PM ET
    $HTGC
    Investment Managers
    Finance

    Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    5/9/25 4:22:04 PM ET
    $HTGC
    Investment Managers
    Finance

    $ZETA
    $IPSC
    $HCXY
    $XMTR
    SEC Filings

    View All

    SEC Form 10-Q filed by Century Therapeutics Inc.

    10-Q - Century Therapeutics, Inc. (0001850119) (Filer)

    8/14/25 4:21:09 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Century Therapeutics, Inc. (0001850119) (Filer)

    8/14/25 4:17:08 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Xometry Inc.

    SCHEDULE 13G/A - Xometry, Inc. (0001657573) (Subject)

    8/13/25 5:08:32 PM ET
    $XMTR
    Real Estate

    $ZETA
    $IPSC
    $HCXY
    $XMTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Kroll Bond Rating Agency, Inc. ("KBRA") has affirmed Hercules' investment grade corporate and credit rating of BBB+. KBRA issued a statement announcing the affirmation of the rating and stable outlook, as well as its underlying analysis. The affirmed BBB+ rating reflects the Company's diversified investment portfolio with a focus on senior secured first lien venture debt investments in the technology

    8/19/25 6:00:00 AM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance

    Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025CNTY-308, a CAR-iT cell therapy functionally comparable to primary T cells, now in IND-enabling studies as a potential treatment for B-cell-mediated diseases; program expected to progress into the clinic in 2026 Dr. Brent Pfeiffenberger, CEO, appointed to Board ChairCash runway extended into fourth quarter 2027 PHILADELPHIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune dis

    8/14/25 4:01:00 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xometry to Participate in Upcoming Investor Conferences

    NORTH BETHESDA, Md., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Xometry, Inc. (NASDAQ:XMTR), the global AI-powered marketplace connecting buyers with suppliers of manufacturing services, announced that members of its management team will attend the following investor events: Citi's 2025 Global TMT Conference: September 3rd, in New York City – including a fireside chat at 3:30 p.m. ETGoldman Sachs Communacopia & Technology Conference: September 10th, in San Francisco – including a fireside chat at 12:25 p.m. PT Webcasts and replays of the fireside chats will be accessible within the Investor Relations section of Xometry's website following each session. About XometryXometry's (NASDAQ:XMTR) AI-pow

    8/13/25 9:00:00 AM ET
    $XMTR
    Real Estate

    $ZETA
    $IPSC
    $HCXY
    $XMTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Xometry upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Xometry from Underweight to Neutral and set a new price target of $41.00

    8/5/25 3:53:08 PM ET
    $XMTR
    Real Estate

    Needham resumed coverage on Zeta Global with a new price target

    Needham resumed coverage of Zeta Global with a rating of Buy and set a new price target of $20.00

    6/10/25 8:09:48 AM ET
    $ZETA
    Computer Software: Prepackaged Software
    Technology

    Cantor Fitzgerald resumed coverage on Sprinklr with a new price target

    Cantor Fitzgerald resumed coverage of Sprinklr with a rating of Neutral and set a new price target of $8.00

    6/3/25 8:05:55 AM ET
    $CXM
    Computer Software: Prepackaged Software
    Technology

    $ZETA
    $IPSC
    $HCXY
    $XMTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Pfeiffenberger Brent was granted 1,587,614 shares, increasing direct ownership by 94% to 3,269,397 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    8/18/25 4:14:36 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Rollins Emily exercised 350 shares at a strike of $12.32, increasing direct ownership by 3% to 11,455 units (SEC Form 4)

    4 - Xometry, Inc. (0001657573) (Issuer)

    8/12/25 4:26:22 PM ET
    $XMTR
    Real Estate

    SVP Finance & Operations Carr Douglas sold $158 worth of shares (296 units at $0.53), decreasing direct ownership by 0.07% to 405,686 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    8/6/25 4:13:49 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZETA
    $IPSC
    $HCXY
    $XMTR
    Financials

    Live finance-specific insights

    View All

    Sprinklr Announces Date of Second Quarter Financial Results

    Sprinklr (NYSE:CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced that the company's second quarter of fiscal year 2026 financial results will be released before market open on September 3, 2025. The company's earnings press release will be made available on the Sprinklr Investor Relations website at investors.sprinklr.com. Sprinklr will host a conference call to discuss its results at 8:30 am ET the same day. Interested parties may register for and access the live webcast of the call at the Sprinklr Investor Relations website. To access the call by phone, dial 877-459-3955 (domestic) or 201-689-8588 (international). The confere

    8/13/25 8:00:00 AM ET
    $CXM
    Computer Software: Prepackaged Software
    Technology

    Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

    CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and support long-term growth. The multi-faceted refinancing transaction consisted of the following key components: A new senior credit facility with Hercules Capital, Inc. (NYSE:HTGC), due in 2030, which provides $110.0 million in committed capital at closing and an additional $40.0 million in two $20.0 million tranches available upon achievement of certain milestones, to be drawn at the Company's discretion;An exc

    8/8/25 7:45:00 AM ET
    $HRTX
    $HTGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    Privia Health Reports Second Quarter 2025 Financial Results

    Very Strong First Half Performance Across All Key Operating and Financial MetricsImplemented Providers +13.8% and Practice Collections +18.5% compared to 2Q'24Guidance Raised to Above High End of Range for Practice Collections, GAAP Revenue, Platform Contribution and Adjusted EBITDA c ARLINGTON, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) today announced financial results for the second quarter ended June 30, 2025. Second Quarter Performance   For the Three Months Ended June 30,  ($ in millions, except per share amounts)  2025  2024 Change (%)       Total revenue $521.2 $422.3 23.4%Gross profit $112.8 $98.3 14.8%Operating income $3.3 $5.1 (34.6)%Ne

    8/7/25 6:00:00 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    $ZETA
    $IPSC
    $HCXY
    $XMTR
    Leadership Updates

    Live Leadership Updates

    View All

    Sprinklr Welcomes Bit Rambusch as Head of Global Services and Support.

    Sprinklr (NYSE:CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced that Bit Rambusch has joined Sprinklr as Head of Global Services and Support, reporting to Sprinklr President and CEO, Rory Read. "We are thrilled to welcome Bit to the Sprinklr team. With his proven track record of building and scaling world-class customer service organizations and deep technical expertise, Bit brings the operational rigor and strategic vision we believe is critical as we continue our transformation journey," said Sprinklr President and CEO, Rory Read. "Our services and support organizations are a vital element of our strategy to reenergize and g

    8/7/25 8:00:00 AM ET
    $CXM
    Computer Software: Prepackaged Software
    Technology

    Snappt Acquires Trigo to Enhance Applicant Trust Platform for Multifamily Housing, Secures $50M Growth Financing

    Strategic growth financing accelerates expansion through acquisition and supports product innovation Snappt, the leading platform for applicant trust in multifamily housing, today announced it has acquired Trigo, a company known for its breakthrough technology in verifying rental payment history. Backed by a $50 million committed facility from Hercules Capital, Inc. (NYSE:HTGC), the acquisition expands Snappt's platform and strengthens its ability to help property managers make faster, more confident leasing decisions. Together, these milestones mark a major step toward building the industry's most complete and trusted solution embedded into the application and screening process. "This

    8/5/25 12:00:00 PM ET
    $HTGC
    Investment Managers
    Finance

    Zeta Global Appoints Nate Yohannes as President of Zeta Data & AI Lab to Accelerate AI Innovation

    Former Meta and Microsoft senior leader to oversee innovation hub focused on developing next-gen agentic tools and technologies for the modern marketer Zeta Global (NYSE:ZETA), the AI Marketing Cloud, today announced the appointment of Nate Yohannes as President of Zeta Data & AI Lab and Global Head of Research and Development. A proven leader at the intersection of artificial intelligence and product innovation, Yohannes brings over 15 years of experience spanning senior roles at Meta, Microsoft, and the White House. Most recently, he served as Product Management Lead for GenAI in Ads Ranking at Meta, where he led the strategy and development of AI systems built on Meta's Llama to enhanc

    7/29/25 4:05:00 PM ET
    $ZETA
    Computer Software: Prepackaged Software
    Technology

    $ZETA
    $IPSC
    $HCXY
    $XMTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Century Therapeutics Inc.

    SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

    11/27/24 6:51:58 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Zeta Global Holdings Corp.

    SC 13G - Zeta Global Holdings Corp. (0001851003) (Subject)

    11/18/24 7:13:53 AM ET
    $ZETA
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:48:20 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care